

Thoughts from a Decision-Maker (One of Many)

Laura Lee Johnson, PhD
Director, Division of Biometrics III
Office of Biostatistics
Office of Translational Sciences
Center for Drug Evaluation and Research (CDER)



The views expressed in this presentation are those of the speaker, and do not necessarily represent an official FDA position



ISPOR Framework

Context

Purpose

Population

Method

Impact

Considerations









WHAT DOES THE
DECISION MAKER
NEED AND WHAT WILL
THEY FIND USEFUL



BUDGET TIME TO TALK
TO DECISION-MAKERS
(REGULATOR, HTA,
ETC.)











Talk to your expert consultants before talking to the decision-maker [do not delay talking directly to the decision makers]

There is a lot of other information a decision-maker is also considering

relevant to our questions

https://www.fda.gov/about-fda/cdrh-patient-science-andengagement-program/patient-preference-information-ppimedical-device-decision-making https://www.fda.gov/drugs/developmentapproval-process-drugs/cder-patient-focuseddrug-development




Thoughts Beyond "Come Talk to Us"

- Not just the answer or the results
 - Justify decisions
 - What compromises were made? Why?
 - Documentation
 - Decide not to do the study? Why?
- If you want comments on your study, ask a question about it
 - [CDER: might be a WRO Type C meeting]
 - [CDRH: pre-submission process; CDRH Patient Science & Engagement team]
 - Submit the protocol (with a question)
 - CRO? Consultant?
 - Ask for the exact comments/advice letter from FDA/the decision-maker
 - "Strongly recommend" "Recommend"
- Do not need to do everything in one study

Helpful Questions









WHAT ARE THEY WEIGHING AND WHY?



WILL YOUR STUDY HELP THEM MAKE THE DECISION THEY NEED TO MAKE?

Participants' Time Matters: Use methods that can answer the questions decision makers are trying to answer









PURPOSE

PRINCIPLES

SCIENCE

